Clinical Trials Logo

Plasminogen Deficiency clinical trials

View clinical trials related to Plasminogen Deficiency.

Filter by:
  • None
  • Page 1

NCT ID: NCT05404932 Recruiting - Clinical trials for Plasminogen Deficiency

Treatment of Ligneous Conjunctivitis in Children With Plasminogen Deficiency

Start date: December 15, 2022
Phase: N/A
Study type: Interventional

Congenital plasminogen deficiency causes impaired wound healing and growth of pseudomembranous lesions over multiple parts of the body. The most common lesions involve eyes and are known as Ligneous conjunctivitis. These can cause scarring of the sclera, vision loss and even blindness. These pseudomembranous lesions are recur after surgical excisions, administration of intra-ocular cyclosporine, autologous serum drops or corticosteroids. Clinical data shows that these growths do not worsen and do not recur after administration of plasminogen (either as concentrate or as plasma) in the eyes, locally or intravenously. As plasminogen is not available as concentrate, we are using aliquoted allogenic plasma provided by Canadian Blood Services for intra-ocular application. These will be applied to eyes multiple times a day for a period of 2 to 6 months depending on disease severity and patient response. These may be used again if ligneous conjunctivitis recurs. The patient will be followed for a period of 2 years at least. All serious adverse events will be reported to Canadian Blood Services and Health Canada as appropriate.

NCT ID: NCT03797495 Recruiting - Clinical trials for Plasminogen Deficiency

Study of Individuals Affected With Hypoplasminogenemia

HISTORY
Start date: December 18, 2018
Phase:
Study type: Observational

This is an Investigator initiated retrospective and prospective single cohort study. The study will utilize an international registry and develop a specimen biobank to provide an improved understanding of the natural history of hyposplasminogenemia, to elucidate the heterogeneity of phenotypic expression, identify markers to predict disease course, and inform improved therapeutic modalities